Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
Clin Infect Dis
; 50(8): 1192-7, 2010 Apr 15.
Article
em En
| MEDLINE
| ID: mdl-20210643
ABSTRACT
Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
RNA Viral
/
Infecções por HIV
/
Inibidores da Protease de HIV
/
Fármacos Anti-HIV
/
Carga Viral
/
Adesão à Medicação
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article